pCPA File Number: 21749
Under consideration for negotiation
In combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen
Novartis Pharmaceuticals Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: